SAN DIEGO, CA — January 5, 2026 — Leads & Copy — Halozyme Therapeutics, Inc. and Skye Bioscience, Inc. have announced a non-exclusive global collaboration and license agreement, effective as of December 2025.
Under the agreement, Skye Bioscience has secured a license to utilize Halozyme’s ENHANZE® drug delivery technology for the development and potential commercialization of a subcutaneous formulation of nimacimab, targeting the treatment of obesity. The collaboration aims to facilitate Skye’s assessment of higher subcutaneous doses of nimacimab through the delivery of larger injection volumes.
Dr. Helen Torley, President and Chief Executive Officer of Halozyme, stated that the collaboration with Skye Bioscience expands the application of their ENHANZE technology into the growing obesity market, noting its significant long-term potential. The agreement also underscores the scalability of ENHANZE across various indications and supports Halozyme’s strategy to promote sustainable royalty growth through new partnerships and innovations.
Punit Dhillon, President and Chief Executive Officer of Skye, emphasized the necessity of testing higher doses of nimacimab with a practical method for subcutaneous delivery to fully evaluate its potential. Dhillon stated that partnering with Halozyme to co-formulate nimacimab with ENHANZE provides them with a validated approach to evaluate multiple dose-ranging strategies, including combinations with GLP-1 receptor agonists.
Skye Bioscience will make milestone payments contingent upon achieving specific development and commercialization milestones. Halozyme is also set to receive mid-single digit royalties on net sales of nimacimab developed using ENHANZE® for a minimum of 10 years.
Skye Bioscience plans to initiate a Phase 2b clinical trial in mid-2026 to study nimacimab with ENHANZE in obesity. This trial will also assess the combination of nimacimab with a GLP-1R agonist.
Halozyme is a biopharmaceutical company focused on advancing solutions to enhance patient experiences and outcomes for both emerging and established therapies.
Halozyme’s ENHANZE® drug delivery technology, featuring the proprietary enzyme rHuPH20, facilitates subcutaneous delivery of injected drugs and fluids, which reduces treatment burden and improves convenience. The technology has reached over one million patients through ten commercialized products across more than 100 global markets and is licensed to pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, and Merus N.V.
Halozyme is also developing Hypercon™, a microparticle technology designed to enhance the concentration of drugs and biologics, which can reduce injection volume and expand at-home and health care provider administration options. The Hypercon™ technology has been licensed to Johnson & Johnson, Eli Lilly, and argenx.
The company also develops, manufactures, and commercializes drug-device combination products using advanced auto-injector technologies to improve patient comfort and adherence. Halozyme’s proprietary commercial products include Hylenex® and XYOSTED®, and it has partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in San Diego, CA, with additional offices and an operations facility in various locations.
Skye Bioscience focuses on developing next-generation molecules that modulate G-protein coupled receptors to unlock new therapeutic pathways for metabolic health. The company is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study will also assess the combination of nimacimab and a GLP-1R agonist (Wegovy®).
Contacts:
Halozyme
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Skye Investor & Media Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors
Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Source: Halozyme Therapeutics, Inc.
